menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Gilead Reveals New HIV Treatment and Cure Data at CROI 2025

    BUSINESSWIRE

    Gilead sets aside $200M for settlement over HIV drug

    FIERCE PHARMA

    MEDSIR, Debiopharm Dose First Patient In WIN-B Breast Cancer Trial

    BUSINESSWIRE

    EMA Validates Gilead’s MAA For Lenacapavir In HIV Prevention

    BUSINESSWIRE

    Gilead`s Seladelpar Gets EU Conditional Nod For Biliary Cholangitis

    BUSINESSWIRE

    Gilead Showcases Autoimmune Impact In The Centrifuge Sessions

    ACCESSWIRE

    Gilead Sciences to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    FDA Grants Review To Gilead’s Lenacapavir For HIV Prevention

    BUSINESSWIRE

    Nurix Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Ideaya & Gilead To Study Trodelvy + IDE397 Combo In MTAP-Deleted NSCLC

    PR NEWSWIRE

    Gilead provides upbeat 2025 forecast, shares rise 4%

    REUTERS

    GSK questions Gilead`s potential dominance of the PrEP market

    FIERCE PHARMA

    Energize Supports Global Healthcare Firms with Multi-buyer PPA

    BUSINESSWIRE

    Gilead to Release Q4 & Full Year 2024 Financial Results Feb 11

    BUSINESSWIRE

    Gilead, US government resolve long-running HIV patent dispute

    PRESS RELEASE

    Gilead, LEO Pharma to programs for inflammatory diseases

    REUTERS

    Galapagos splits in 2, laying off 40% of staff

    FIERCE BIOTECH

    Gilead Sciences to Present at Upcoming Investor Conference

    BUSINESSWIRE

    Merck`s HIV combo treatment meets efficacy bar in Ph 3 trials

    FIERCE BIOTECH

    Gilead & Terray Announce Multi-Target Research Collaboration

    BUSINESSWIRE

    AI-powered Terray is teaming up with Gilead in a fresh R&D pact

    FIERCE BIOTECH

    Gilead`s Seladelpar Receives CHMP Nod For Biliary Cholangitis

    BUSINESSWIRE

    Gilead appoints Sanofi official Dietmar as next CMO

    REUTERS

    ICER calls out drugmakers over `unsupported` price hikes

    REUTERS

    Gilead spotlights lenacapivir in plan to hold on to HIV crown

    FIERCE PHARMA

    Kite’s Tecartus CAR T Therapy Shows Durable Efficacy at ASH 2024

    BUSINESSWIRE

    Kite`s Yescarta® Shows Durable Response in Relapsed Lymphomas

    BUSINESSWIRE

    Kite`s Yescarta® Highlights Curative Potential in Relapsed Lymphoma

    BUSINESSWIRE

    Gilead taps Tubulis for solid tumor ADC development worth up to $465M

    PRESS RELEASE

    Gilead Announces NEJM Publication of PURPOSE 2 Results

    BUSINESSWIRE

    Designing Inclusive Trials in an Effort To Upend the HIV Epidemic

    ACCESSWIRE

    Gilead buys HIV vaccine from biotech following clinical collab

    FIERCE BIOTECH

    Gilead supports ‘sanctuary’ for Black breast cancer patients

    FIERCE PHARMA

    Ideaya hires Gilead leader to head up commercialization push

    FIERCE PHARMA

    Gilead cuts 100+ positions at California HQ

    FIERCE PHARMA

    Gilead’s Livdelzi Shows Sustained Efficacy in Biliary Cholangitis

    BUSINESSWIRE

    Gilead to lay off 72 staffers, shutter Seattle R&D office

    FIERCE BIOTECH

    Gilead Presents PURPOSE 2 Data on Lenacapavir for HIV Prevention

    BUSINESSWIRE

    Gilead Prices $3.5 Billion of Senior Unsecured Notes

    BUSINESSWIRE

    Gilead Presents Research on Broad HIV Treatment Portfolio

    BUSINESSWIRE

    Gilead`s CAR-T sales stagnate as Trodelvy takes another write-off

    FIERCE PHARMA

    Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged

    FIERCE PHARMA

    Gilead Sciences to Present at Upcoming Investor Engagements

    BUSINESSWIRE

    Gilead Presents Data & Extends HIV Leadership at HIV Glasgow

    BUSINESSWIRE

    Gilead Q3 results beat Wall Street estimates, raises outlook

    REUTERS

    Gilead Sciences Announces Q3 2024 Financial Results

    BUSINESSWIRE

    Kite to Present CAR T-Cell Therapy Data at ASH 2024

    BUSINESSWIRE

    ASH: Gilead-Arcellx data build CAR-T`s case in advanced myeloma

    FIERCE BIOTECH

    Gilead Oncology Grant Supports 22 U.S. Breast Cancer Organizations

    ACCESSWIRE

    Gilead To Present Research At AASLD Meeting 2024

    BUSINESSWIRE

    Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks

    FIERCE BIOTECH

    Gilead withdraws bladder cancer drug in US after failed trial

    REUTERS

    GSK bolsters case for long-acting HIV PrEP drug Apretude

    FIERCE PHARMA

    Gilead gives up on $15M MASH bet after mulling preclinical data

    FIERCE BIOTECH

    Gilead To Present Late-Breaking Data At IDWeek 2024

    BUSINESSWIRE

    Gilead To Release Q3 2024 Results November 6

    BUSINESSWIRE

    Enforcement Report - Week of October 9, 2024

    FDA

    Gilead: Report Shows Countries Must Do More To End HIV Epidemic

    ACCESSWIRE

    Gilead Presents Data From PURPOSE 2 Trial At HIV Conference

    BUSINESSWIRE

    Emcure Pharma partners with Gilead Sciences to produce HIV drug

    PRESS RELEASE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.